ViruCure Therapeutics
Oncolytic Virus-based Technology Platform for Treating Cancer
Company Overview
Snapshot
Founded in September 2016 by Yoram Drucker and Shay Tayeb, ViruCure Therapeutics operates with 1–10 employees. The company has secured funding across one round. ViruCure Therapeutics ceased operations in December 2024.
Business overview
ViruCure Therapeutics is a biotechnology company focused on developing NADAV, an oncolytic Newcastle disease virus (NDV) platform designed for the treatment of various cancer types. This proprietary technology, developed at the Hebrew University of Jerusalem, specifically targets cancerous cells, replicates within them, and triggers an anti-tumoral immune response with low toxicity to normal tissues. The initial therapeutic targets for the platform include glioblastoma multiforme and lung cancer patients. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, and is engaged in drug discovery and development, cell therapy, and oncology.
Log in to access full profile ›Company Intelligence Q&A
- What is ViruCure Therapeutics' primary focus?
- ViruCure Therapeutics develops NADAV, an oncolytic Newcastle disease virus (NDV) platform for treating a wide range of cancer types, including glioblastoma multiforme and lung cancer.
- When was ViruCure Therapeutics founded?
- ViruCure Therapeutics was founded in September 2016.
- Who are the founders of ViruCure Therapeutics?
- The company was co-founded by Yoram Drucker, who serves as CEO, and Shay Tayeb, who serves as CTO.
- What is the status of ViruCure Therapeutics?
- ViruCure Therapeutics is currently non-active, having ceased operations in December 2024.
- What is the core technology behind ViruCure Therapeutics' cancer treatment?
- The core technology is NADAV, an oncolytic Newcastle disease virus (NDV) platform that selectively targets and replicates in cancer cells, inducing cell death and activating the host's immune response against tumors.